FDA Clearance for Treatment of Anxious DepressionSTIM: Neuronetics
2022-07-19 07:00:00
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
−1.06USD
−30.19 MUSD
71.35 MUSD
26.66 M
About Neuronetics, Inc.
Sector
Industry
CEO
Keith J. Sullivan
Website
Headquarters
Malvern
Employees (FY)
203
Founded
1998
FIGI
BBG000QX36J1
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.
STIM BullishI like the recent MACD cross and that the most recent candle tested two fib levels and closed over the .382 level. Also after an extreme sell off price seems to have bottomed at 4.61. The ADX shows a relatively strong trend with the directional indicators moving in a bullish direction.
targeting:
STIM BullishMACD is crossing and the price has consolidated around $12.17 for several trading days. I will try to add between $12.17 and $11.60 with a stop at at $11.36
Target: $16.34
$STIM LONG - looks like price want to go higher$STIM - looks like it might be good here for a long position.
My stop is $16.50
$STIM - may have missed the moveI should have got in yesterday.
I am considering an entry tomorrow on a pull back.
It's opex so we may get one.
I like swinging this stock.
$STIM - biotech category - same indicators as the others$STIM - added to my biotech/genome category
It has the same "chicken-beak" patterns as EDIT, CRSP, BNGO and others.
I'm swinging this stock. It has buyer support at $14.00 level. We are barely above that, so feels ok to keep adding to this swing trade.
Follow the trend Lets see if this wanna play to target 8+
Just to follow the stock
but i see a small retrancement befor it keep going forward
STIM BULLISH STIM looks like its ready for its next leg up as the MACD starts to cross, it broke thru the descending trendline today and today's candle closed above 6.34 (100% Fib level) assuming it can break thru resistance at 6.85 I think this goes much higher. First target 7.82 and on to 10.21 in the longer t
STIM Very Bullish The STIM chart looks very bullish with a recent MACD cross and the 9ema crossing the 20ema. Also the .23 fib level was tested twice and should act as a support level. First target 5.82 then 6.26 in the short term.
$STIM Neuronetics, Inc. 60% Potential Upside Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of STIM is 3.74 USD — it has decreased by 1.58% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neuronetics, Inc. stocks are traded under the ticker STIM.
Neuronetics, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
STIM stock is 4.61% volatile and has beta coefficient of 2.59. Check out the list of the most volatile stocks — is Neuronetics, Inc. there?
STIM earnings for the last quarter are −0.33 USD per share, whereas the estimation was −0.31 USD resulting in a −6.45% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about Neuronetics, Inc. earnings.
Neuronetics, Inc. revenue for the last quarter amounts to 17.88 M USD despite the estimated figure of 17.58 M USD. In the next quarter revenue is expected to reach 19.85 M USD.
Yes, you can track Neuronetics, Inc. financials in yearly and quarterly reports right on TradingView.
STIM stock has fallen by 14.22% compared to the previous week, the month change is a 12.82% fall, over the last year Neuronetics, Inc. has showed a 72.35% increase.
STIM net income for the last quarter is −5.38 M USD, while the quarter before that showed −9.39 M USD of net income which accounts for 42.74% change. Track more Neuronetics, Inc. financial stats to get the full picture.
Today Neuronetics, Inc. has the market capitalization of 111.29 M, it has increased by 6.39% over the last week.
No, STIM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, STIM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neuronetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 203.00 employees. See our rating of the largest employees — is Neuronetics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neuronetics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neuronetics, Inc. stock shows the neutral signal. See more of Neuronetics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Neuronetics, Inc. future price: according to them, STIM price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Read a more detailed Neuronetics, Inc. forecast: see what analysts think of Neuronetics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neuronetics, Inc. EBITDA is −28.55 M USD, and current EBITDA margin is −40.01%. See more stats in Neuronetics, Inc. financial statements.